English
Home > Products > CAS NO 1643-19-2

China CAS NO 1643-19-2 Factory

We now have quite a few superb workers customers very good at marketing and advertising, QC, and working with forms of troublesome dilemma while in the creation approach for CAS NO 1643-19-2,1643-19-2,CAS NO 10549-76-5,10549-76-5,Tetrabutyl ammonium, We aim at Ongoing system innovation, management innovation, elite innovation and market innovation, give full play to the overall advantages, and constantly improve service quality.
CAS NO 1643-19-2, Our next goal is to exceed the expectations of every client by offering outstanding customer service, increased flexibility and greater value. All in all, without our customers we do not exist; without happy and fully satisfied customers, we fail. We have been looking for the wholesale, Drop ship. Please contact us if you are interesting our items. Hope to do business with you all. High quality and fast shipment!

Related Products

Hot Products

  • Camptothecin

    Camptothecin

    Product Name:Camptothecin
    Molecular Formula:C20H16N2O4
    Molecular Weight:348.35
    CAS Registry Number;7689-03-4
  • Theophylline

    Theophylline

    Product Name:Theophylline
    Molecular Weight:180.16
    CAS Registry Number:58-55-9
  • Ipragliflozin

    Ipragliflozin

    Product Name:Ipragliflozin
    Molecular Formula:C21H21FO5S
    Molecular Weight;404.45
    CAS Registry Number;761423-87-4
  • Gatifloxacin Mesylate

    Gatifloxacin Mesylate

    Product Name:Gatifloxacin Mesylate
    Molecular Formula:C19H22FN3O4.CH4O3S
    Molecular Weight;471.503
    CAS Registry Number;316819-28-0
  • CMC﹒HCL

    CMC﹒HCL

    Product Name:CMC﹒HCL
    Molecular Formula:C10H14ClN3O4
    Molecular Weight:275.68886
    CAS Registry Number:51391-96-9
  • 2-Amino-3-benzyloxypyridine

    2-Amino-3-benzyloxypyridine

    Product Name:2-Amino-3-benzyloxypyridine
    Molecular Formula:C12H12N2O
    Molecular Weight:200.24
    CAS Registry Number:24016-03-3
  • Related Blog
  • Reviews

  • Development Trend of China's Pharmaceutical Intermediate Industry

    The rapid development of China's pharmaceutical intermediate industry is closely related to its national policies. Since 2016, China has issued clear documents to encourage small and medium-sized enterprises to develop new drugs, including chemical raw materials. At the same time, the structural upgrading of the pharmaceutical industry in developed countries has promoted the transfer of global related industrial chains and promoted China's chemical raw material drug supply chain. In addition, the increase in Chinese radiography technology has boosted product demand.

  • What are pharmaceutical intermediates?

    Pharmaceutical intermediates are fine chemical products in the production process from pharmaceutical chemical raw materials to bulk drugs or drugs. The synthesis of chemical drugs depends on high-quality pharmaceutical intermediates. This chemical, which does not require a drug production license, can be produced in ordinary chemical plants and can be used in the synthesis of drugs as long as it reaches certain grades.

  • Tofacitinib More Effective, Alone and in Combinations, than Non-biologic DMARDS

    Tofacitinib (marketed under the brand name Xeljanz) is an oral Janus kinase inhibitor currently approved for the treatment of RA. It was developed in a unique public-private partnership between the National Institutes of Health...

  • Differences Between Pharmaceutical Raw Materials, Excipients and Pharmaceutical Intermediates

    In the pharmaceutical industry, there are various names of raw materials, such as pharmaceutical raw materials, pharmaceutical intermediates and pharmaceutical excipients in the process of pharmaceutical production. This article will take everyone to recognize these three concepts.

  • FDA approves lorlatinib for second- or third-line treatment of ALK-positive metastatic NSCLC

    On November 2, 2018, the Food and Drug Administration granted accelerated approval to lorlatinib (LORBRENA, Pfizer, Inc.) for patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) whose disease has progressed on crizotinib and at least one other ALK inhibitor for metastatic disease or whose disease has progressed on alectinib or ceritinib as the first ALK inhibitor therapy for metastatic disease.

  • CAS No. 144689-24-7 Olmesartan Introduction

    Olmesartan is an angiotensin II receptor blocker, widely used for the treatment of hypertension. The Renin-Angiotensin-Aldosterone System (RAAS) plays an importent role in the development and progression of many diseases such as hypertension...

Send Inquiry

Hit enter to search or ESC to close
X
We use cookies to offer you a better browsing experience, analyze site traffic and personalize content. By using this site, you agree to our use of cookies. Privacy Policy
Reject Accept